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Thomson and Nielsen TN-502 RD MOSFETs were used for entrance dose in vivo dosimetry for 6 and 10 MV photons. A 
total of 24 patients were tested, 10 breast, 8 prostate, 5 lung and 1 head and neck. For prostates three fields were checked. 
For all other plans all fields were checked. An action threshold of 8% was set for any one field and 5% for all fields 
combined. The total number of fields tested was 56, with a mean discrepancy of 1.4% and S.D. of 2.6%. Breasts had a mean 
discrepancy of 1.8% and S.D. of 2.8%. Prostates had a mean discrepancy of 1.3% and S.D. of 2.9%. For 3 fields combined, 
prostates had a mean of 1.3% and S.D. of 1.8%. These results are similar to results obtained with diodes and TLDs for the 
same techniques.  
 
 






Entrance dose in vivo dosimetry is a well established 
practice worldwide, with guidelines written by both 
ESTRO1 and the AAPM2 on the implementation of diode 
entrance dose in vivo dosimetry. It has shown its usefulness 
as a means of detecting errors that would have passed 
through the treatment chain unnoticed and affected patient 
outcome3-4. Even with Record and Verify (R&V) systems 
in place errors can be made and left undetected4. 
Studies have been carried out with TLD’s and diodes, 
giving typical mean discrepancies and standard deviations 
for different treatments3,5-16.  
MOSFETs have also been evaluated as an in vivo 
dosimeter, and have been found to be suitable as an in vivo 
dosimeter17-19. Comparisons between diodes and MOSFETs 
have been made with a build up cap showing that the total 
uncertainty with diodes is similar to that of MOSFETs for 
entrance dose in vivo dosimetry measurements20. The 
addition  of  a  build  up  cap  with  high  energy  photons is  
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essential for entrance dose in vivo dosimetry as low energy 
contamination at the surface needs to be removed and 
electronic equilibrium established for reliable entrance dose 
in vivo dosimetry measurements1,2,20. 
MOSFETs have been shown to be suitable as an 
entrance dose in vivo dosimeter in Total Body Irradiation 
(TBI)21. They have also been used for in vivo dosimetry in 
inter operative radiotherapy22, as well as a surgically 
implantable in vivo dosimeter23-25. 
To date no studies have been presented showing results 
of entrance dose in vivo dosimetry for 3D conformal 
radiotherapy (3DCRT) using MOSFETs. Studies have, 
however been done on 10 MV IMRT prostates with a brass 
build up cap26. IMRT is different in its application to 
3DCRT in that in 3DCRT accessories such as wedges and 
blocks are often used to “conform” the beam to the shape 
desired. 3DCRT normally employs MLC leaves and/or 
blocks to define the field shape, and, where necessary 
wedges (either hard or dynamically created) to modulate 
the dose to the tumour volume. The presence of these 
accessories adds extra correction factors and uncertainties 
to entrance dose in-vivo dosimetry that would not be 
present in an IMRT plan20,26. In IMRT the use of blocks and 
wedges is removed. Dose modulation is achieved by 
delivering a dose distribution using MLC leaves using 
either step and shoot or dynamic delivery, or by introducing 
a compensator to the beam. Due to the different nature of 
beam delivery there is a direct relationship between the 
central axis dose and the dose to another point on a plan in 
a 3DCRT plan when a wedge is used. This is not true for 
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IMRT. In IMRT cases the relationship is determined by 
dose optimization algorithms. This means that an entrance 
dose measurement check for a 3DCRT field will give an 
estimate of the error for the whole field. In the case of 
IMRT a dose fluence check is performed on a patient by 
patient basis. 
This paper covers the clinical use of MOSFETs for 
entrance dose in vivo dosimetry for 6 MV and 10 MV 
photons for 3DCRT plans.  
 
 
Materials and methods 
 
MOSFET calibration and characteristics 
Thomson and Nielsen TN-502 RD standard sensitivity 
isotropic MOSFETs were used. A single MOSFET was 
placed in a hemispherical aluminium build up cap. The X-
ray beam energies were 6 and 10 MV on a Siemens Primus, 
and 6 MV on a Siemens Mevatron. The bias supply used 
was the Thomson and Nielsen TN-RD-22 bias supply with 
the bias set to normal. 
Prior to implementation of MOSFETs for in vivo 
dosimetry they were investigated thoroughly for angular, 
field size, and SSD (dose rate) dependence, constancy, 
dose-reproducibility, and linearity without a build up cap. 
Angular, field size, SSD, wedge and tray correction factors 
were also studied in a build up cap. With a build up cap 
correction factors were necessary for field size, wedge and 
trays27. These correction factors were included in entrance 
dose calculations. 
Calibration was performed regularly against an ion 
chamber traceable to a primary standards laboratory 
(ARPANSA). The MOSFET calibration mV/Gy was 
constant, with a standard deviation of 2.6% over a period of 
6 months27. 
 
Phantom study prior to clinical implementation 
To suitably implement IVD in a clinical setting 
uncertainties involved in the measurement should be 
studied beforehand. An action threshold is generally given 
above which the measurement is either repeated and/or the 
setup investigated1. 
The action threshold should not be chosen arbitrarily as 
choosing the wrong action threshold can lead to time 
wasted on investigations into errors which do not exist15. 
This in turn leads to lack of confidence in the new 
techniques being offered. Action levels are based on 2 
standard deviations from the mean measurement1,15. For a 
centre with calibrated diodes and a program in place to 
implement in vivo dosimetry regularly this is about 5 to 
8%1. 
Very few centres have an average standard deviation of 
less than 2.9% (1 S.D.) from the expected mean of 1.001, 
while the standard deviation and mean of results varies 
from centre to centre, as well as from one treatment to the 
next 1. Typically the error will be distributed normally 
around a mean. The standard deviation of this error can 
then be used to determine the action level that a department 
needs to check errors in setup or parameters1.  
Prior to patient measurements plans were created for a 
lung/thorax phantom. This phantom consisted of a central 
bony structure like a spine, with lung density material for 
lungs and water equivalent material for the rest. The plans 
created were designed to test whether entrance dose 
measurements would cope with different scatter and setup 
conditions. The dose calculated with Radcalc was also 
compared to an independently made spreadsheet which 
calculated the dose to the target based on the relationship 
given  in  Equation 1.  These  doses  were  also  compared 
to  the  calculated  dose in the 3D planning system 
(Pinnacle 3D). The percentage difference was taken as the 
difference to Pinnacle 3D at the isocentre with the 
spreadsheet  and the difference to the expected Dmax dose 












−+−=         (1) 
 
where A is the field size, z is the physical depth, Zeff the 
effective depth, B’A the ratio of the backscatters for the 
field size at the isocentre and the entrance (Dmax) (This was 
taken as 1.00), Diso the isocentric dose and, Dent the entrance 
dose. 
A total of 5 plans were created with fields passing 
through lung material and containing normal to high 
obliquity. Each plan consisted of 3 fields. A sample plan is 
included in Figure 1. These plans included hard wedges and 
were delivered for both 6 MV and 10 MV. Dose points 
were placed in tissue equivalent material at the isocentre. 
Entrance dose measurements were compared between the 
spreadsheet and Radcalc to ensure that Radcalc gave 
accurate results for entrance dose measurements. The 
means and standard deviations of all measurements were 
taken. From these means and standard deviations action 
threshold levels were established.  
 
Clinical setup and action thresholds 
Radiation therapists were trained in an informal session 
on the placement of the MOSFET on the patient. The SSD 




Figure 1. Sample lung/thorax plan for testing entrance dose 
measurements.  
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Table 1. Treatment summary. 
 
Treatment Number of patients Number of fields 
Breast 10 20 
Prostate/pelvis 9 27 
Lung/head and neck 3 6 
Head and neck 1 2 
Total 23 55 
 
 
For fields passing through the couch, (eg. PA fields) the 
build up cap was placed on the couch, and the SSD to the 
couch taken. The build up cap was placed on the central 
axis whenever it was possible. For dose estimates from 
MOSFET measurements, Radcalc, a commercially 
available secondary MU checker was used. The Radcalc 
“diode measurement” facility was modified for MOSFET 
entrance dose measurements. Correction factors were made 
in a similar way to diodes and the entrance dose calibration 
factor was added from the MOSFETs27. 
For prostates three measurements were made as 
checking all fields with a seven field prostate treatment 
would take too long. The three fields checked were the AP, 
left and right lateral fields. These three fields give an 
indication of the patient positioning as a displacement or 
incorrect patient setup would result in one of these readings 
being out. At these orientations the beam is also normal to 
the surface of the patient therefore angular dependence and 
would be less significant. It is also easier to place the 
MOSFET at these orientations. For all other treatments all 
fields were tested. 
An action threshold of 8% was set for any single 
measurement based on phantom measurements in a 
lung/thorax phantom. For all fields an action threshold of 
5% was set. If results were outside the action threshold they 
were repeated during the next patient treatment and the 
source of the error investigated. 
A total of 23 patients were tested. Table 1 contains a 
tabulation of treatment delivery types.  
 
Uncertainty 
As MOSFET uncertainty decreases at a rate greater 
than 
D
1 , where D is the dose received by the MOSFET, a 
power relationship for measurement uncertainty was 
adopted based on standard deviations of linearity 
measurements over the range 17.2 to 400 cGy27. The 




2836.1 6485.0−= xσ                                                               (2) 
 
where  x  is the dose in  cGy27.  
For the purposes of this paper a MOSFET measurement 
uncertainty is called uncertainty, a systematic error or 
treatment error is called an error, and the difference 
between the entrance dose reading on a patient and the 
expected reading is called a discrepancy.  
The absolute discrepancy was graphed as a change in 
MOSFET standard deviation would be noticed on a graph 







Of the total of 5 plans (15 fields) the average was 2.0% 
and the standard deviation 3.1%. The maximum difference 
was 6.9%. This was repeated as it was too high. On repeat 
the result was -1.0%. Radcalc and the spreadsheet presented 
similar results to Pinnacle (Table 2). As the standard 
deviation was 3.1% two standard deviations would be 
6.2%. The average typical standard deviation of diodes for 
patient measurements is about 2.8%. As diodes have a high 
precision this 2.8% was added in quadrature to the 3.1% 
from lung/thorax phantom measurements to get a 
representative value for expected dose to the patient. 
Taking 2 times the combined uncertainty for these two 
measurements gives approximately 8%. This was taken as 
the maximum error for any 1 field before investigation. 
Because multiple fields would have a lower uncertainty 
than any one field a tolerance of 5% was set for all fields 
measured for a treatment. These tolerances are also similar 
to those of other institutions1.  
 
Breasts 
Breast results were normally distributed around a mean, 
with an average discrepancy of 1.8% and a standard 
deviation of 2.8% (Figure 2). These results are similar to 
those of other institutions using diodes, and is not worse 
than institutions implementing large scale diode in vivo 
dosimetry (SD= 3.1 and 3.5% for Leuven and Milan 
respectively1).  
 
Prostates and pelvis 
Prostate and Pelvis measurements were grouped 
together. These treatments had results distributed around a 
mean, with an average discrepancy of 1.3% and a standard 
deviation of 2.9%. This is similar to results found in other 
institutions (S.D. 2.7% and 3.0%1), but worse than some 
diode studies might suggest (S.D. 1.5%5 and 1.2%8). 
Absolute    measurement    discrepancy   did   not   decrease  
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Table 2. Lung/thorax phantom results. 
 
Plan Wedge TMR spreadsheet % difference Radcalc % difference 
dp1 6MV   0 -1.3% -1.0% 
dp1 6MV 60 -4.3% -4.7% 
dp1 6MV 45 5.3% 5.0% 
dp2 6MV 15 0.4% 0.4% 
dp2 6MV 30 3.0% 3.3% 
dp2 6MV 15 4.0% 4.0% 
dp3  6MV   0 3.5% 3.2% 
dp3 6MV 15 5.9% 5.9% 
dp3 6MV 30 -0.7% -0.7% 
dp3 6MV   0 3.5% 3.7% 
dp3 6MV 15 -0.2% 0.5% 
dp3 6MV 30 5.9% 6.9% 
dp2 10MV 15 -1.3% -2.2% 
dp2 10MV 30 5.3% 5.0% 
dp2 10MV 30 1.5% -0.4% 
dp3 6MV (repeat) 30 -2.0% -1.0% 
Mean Discrepancy  1.8% 1.7% 
S.D.  3.2% 3.3% 
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Figure 2. Breast measurements. 
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Figure 3. Prostate and pelvis measurements. 
significantly with an increase in dose (r=-0.269, P=0.225) 
(Figure 3, Table 3). This is an important factor as the 
uncertainty of a MOSFET measurement is larger at small 
doses. It would therefore not be unreasonable to expect a 
fall in the standard deviation and average absolute 
discrepancy with an increase in dose. If all 3 fields are 
considered per treatment the mean is 1.3%, and standard 




All the results were distributed around a mean, with a 
mean discrepancy of 1.3% and a standard deviation of 2.6% 
(Figure 4 and Figure 5). The results were slightly 
negatively skewed with a skewness of -0.39 ± 0.33. The 
distribution of results was normal, with a kurtosis of 0.34 ± 
0.67. The average entrance dose delivered per field was 
1.17 Gy. The standard deviation of all measurements was 
2.6%, slightly larger than the expected standard deviation 
of the MOSFET at that dose. Discrepancy means and 
standard deviations for patient measurements for diodes are 
similar to MOSFETs, even though the precision of a diode 
measurement is much greater than a MOSFET 
measurement of the same dose. One can therefore conclude 
that the uncertainties associated with patient setup and 
treatment planning are a limiting factor for entrance dose in 
vivo dosimetry, and that the MOSFET uncertainty, being of 
the same order of magnitude (as a percentage), does not 
significantly increase the uncertainty associated with a 
measurement. 
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Table 3. Prostate/pelvis results. 
 
Prostate SD's Average dose S.D. Theoretical SD Standard error 
Low dose 0.40 3.3% 3.9% 1.2% 
High dose 1.13 2.6% 2.0% 0.6% 
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Figure 4. All measurements. 
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Figure 5. Histogram of results for all measurements. 
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Figure 6. Discrepancy, all treatments excluding breast results. 
Line represents theoretical MOSFET S.D. based on power law. 
All results excluding breast results 
Due to the increased discrepancy associated with breast 
treatments some institutions look at all treatments without 
breast treatments included1. When all treatments except 
breast treatments are considered with the MOSFET 
measurements, the dose-discrepancy relationship shows an 
increase in the standard deviation with a decrease in dose 
(Figure 6). This is similar to the standard deviation of the 
MOSFET. If the MOSFET standard deviation of 
3
2836.1 6485.0−= xσ is plotted against the results the graph 
shows that there is a good fit between the theoretical 
standard deviation and the mean absolute discrepancy 
(Figure 6). The uncertainty in the standard deviation was 
taken as the standard error. If the results are broken into 
three groups (0.3-0.6 Gy, 0.8-1.4 Gy, 1.7-1.8 Gy) the 
standard deviations of the means fall along the theoretical 
standard deviation (Figure 6). This shows that the dose 
measured with the MOSFET is a factor affecting the 
accuracy of the entrance dose measurement for low dose 
measurements. The uncertainty of a measurement can be 
reduced by increasing the bias voltage across the MOSFET, 
but as the means and standard deviations for the treatments 
as a whole are similar to other institutions (Table 4) there is 
little practical advantage from increasing the bias voltage 
and reducing the life expectancy of the MOSFET with the 
exception of prostates and pelvises. 
 
Typical results for different techniques 
Results from entrance dose in vivo dosimetry tend to 
vary from one centre to the next, but large studies from 
Europe give a good indication of which results to expect. 
The results depend on the field type and anatomical 
position. Typically breast and head and neck treatments 





Only one measurement needed to be re-measured. It 
was for a tangential breast and the error was tracked down 
to an incorrect MOSFET reading. As the reading was 
significantly different to the expected reading and SSD and 
MU’s were within tolerance and would not have created 
such a large dose the reading was repeated during the next 
treatment. It was not included in these results. When the 
measurement was repeated the reading was within tolerance 
(8% one field, 5% 2 fields combined). No other 
measurements needed to be re-measured. For all plans 
the total combined discrepancy of all fields was within 5% 
of the prescribed dose.  
The  increase  in  the  standard   deviation   of   Prostate  
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Table 4. Institution means and Standard Deviations for external beam radiotherapy IVD. 
 
Paper/book Technique Mean σ 
Quality assurance by systematic in vivo dosimetry: results 













Implementation of an in vivo diode dosimetry program 
and changes in diode characteristics over a 4-year clinical 
history, Jursinic, 20019 
All 0.5% 1.5% 
Accurate in vivo dosimetry of a randomized trial of 
prostate cancer irradiation, Meijer et al 200110 
Prostate 0.9% 1.2% 
























Tumour dose estimation using automated TLD 










Entrance and exit dose measurements with 
semiconductors and thermoluminescent dosimeters: a 








Feasible measurement errors when undertaking in vivo 
dosimetry during external beam radiotherapy of the 
breast, Herbert C et al 200312 
Tangential Breast 4.3% 4.0% 
Quality assurance in radiation oncology. A study of 
feasibility and impact on action levels of an in vivo 
dosimetry program during breast cancer irradiation, Cozzi 








In vivo dosimetry during conformal radiotherapy. 
Requirements for and Findings of a routine procedure, 
Lanson et al.199914 
The implementation of in vivo dosimetry in a small 










Importance of in vivo dosimetry as part of a quality 
assurance program in tangential breast treatments, 
Leunens G et al. 199315 
Breasts 1.3% 3.4% 
Selective in vivo dosimetry in radiotherapy using P-type 
semiconductor diodes: a reliable quality assurance 
























measurements could be exacerbated by entrance dose 
measurements of low dose. These treatments typically had 
larger standard deviations than diode studies for the same 
techniques. The expected standard deviation of a low dose 
measurement with a MOSFET is larger than the standard 
deviation for a higher dose measurement. Increasing the 
bias voltage will decrease the standard deviation at lower 
doses. This could decrease the standard deviation of in vivo 
measurements, but has not been included in this study.  
For IMRT prostate treatments using a high sensitivity 
bias setting the standard deviation of measurements is 
3.3%, and no trend is observed with increasing dose26. As 
prostate measurements had a standard deviation of 2.9%, 
and that large scale studies with diodes have reported a 
standard deviation of 2.7%1, and no trend was observed, 
increasing the bias to high sensitivity will not, based on 
these results, and bearing in mind that IMRT is a very 
different treatment modality to 3DCRT, reduce the standard 





Thomson and Nielsen TN-502 RD standard sensitivity 
isotropic MOSFETs can be used clinically as entrance dose 
in vivo dosimeters when used with an appropriate build up 
cap. Results are similar to that of diodes and TLD’s, with a 
mean discrepancy of 1.3% ±2.6% for all results. For all 
fields except breast treatments the standard deviation of 
measurements from the expected value increased with 
decreasing dose, showing that for doses less than 0.5 Gy to 
the surface the loss of MOSFET reading precision becomes 
an issue. This issue might be resolved by increasing the 
sensitivity of the bias box for the MOSFETs, but has not 
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